PGH.ASX GQG.ASX AHC.ASX REA.ASX MDR.ASX

Pact Group Faces Delisting Challenges, GQG Partners Declares Dividend, and Austco Healthcare Secures Major US Contract

The Takeovers Panel has received an application from a shareholder regarding Pact Group Holdings' (ASX: PGH) proposed delisting from the ASX. The applicant claims the delisting process is unacceptable, citing concerns over low liquidity, a short window to sell, and the potential for the major shareholder to consolidate ownership. The applicant is seeking various orders to address these issues and improve disclosure.

Elsewhere, GQG Partners Inc. (ASX: GQG) announced a quarterly dividend of US$0.0378 per share, equivalent to AUD$0.058723 per share. This dividend represents 93.3% of the company's estimated first quarter distributable earnings and is consistent with the final 2024 dividend amount. GQG Partners also reported its funds under management (FUM) as at 30 April 2025, with total FUM of $163.6 billion and net flows of $1.4 billion for the month and $6.0 billion year-to-date.

In other news, Austco Healthcare Limited (ASX: AHC) has renewed a preferred supplier agreement with a major US healthcare provider to continue delivering its Tacera IP Nurse Call system and software platform to approximately 180 hospitals across the US. This renewed and expanded contract builds on a previous 5-year agreement that generated over A$49 million in revenue for Austco.

Rounding out the day's announcements, REA Group Ltd (ASX: REA) reported a strong Q3 FY25 result, with revenue up 18% to $1,247m and EBITDA up 19% to $734m. The company's flagship site, realestate.com.au, maintained its market-leading position, reaching record audiences during the quarter. Looking ahead, REA Group expects continued strong buyer demand and modest property price growth, supporting further yield expansion.

Finally, MedAdvisor Limited (ASX: MDR) has provided an update on its strategic review, announcing it has entered a non-binding Letter of Intent to sell its ANZ business division to an Australian subsidiary of a prominent, multinational software company for a headline price of $35 million plus an uncapped earn-out of up to $7.35 million.